文献速递炎症性肠病

英夫利西单抗与乌帕替尼在生物制剂初治的重度内镜下溃疡性结肠炎中显示更优的早期疗效

Infliximab and Upadacitinib Demonstrate Superior Early Onset of Efficacy in Biologic-Naïve Ulcerative Colitis With Severe Endoscopic Disease.
PubMed 文献 · Am J Gastroenterol · 2026-02-02

该研究基于11项随机对照试验的个体数据,事后分析1781例生物制剂初治、Mayo内镜评分3分的溃疡性结肠炎患者。结果显示英夫利西单抗和乌帕替尼第2周PRO-2应答率最高,且诱导后应答率也最优;与MES 2患者相比,MES 3患者对多种治疗的应答几率降低。

要点

  • 英夫利西单抗和乌帕替尼在重度内镜下UC中第2周PRO-2应答率最高。
  • 英夫利西单抗和乌帕替尼诱导后PRO-2应答率同样优于其他药物。
  • MES 3患者对乌司奴单抗、托法替布、维得利珠单抗和米吉珠单抗的应答几率低于MES 2患者。

核心结论

  • 在生物制剂初治的重度内镜下UC患者中,英夫利西单抗和乌帕替尼第2周及诱导后PRO-2应答率最高。
  • 基线疾病活动度可能有助于指导治疗选择。

研究设计与样本

  • 事后分析,使用11项随机对照试验的个体参与者数据。
  • 纳入1781例生物制剂初治、MES 3的UC患者,接受英夫利西单抗、阿达木单抗、戈利木单抗、维得利珠单抗、乌司奴单抗、米吉珠单抗、托法替布或乌帕替尼的标准诱导方案。
  • 主要结局为基线后2周早期PRO-2应答(排便频率和直肠出血评分较基线降低≥50%)。
  • 采用校正基线协变量的逻辑回归模型。

主要发现

  • 英夫利西单抗(35.1%)和乌帕替尼(32.4%)的早期PRO-2应答率最高。
  • 与安慰剂相比,乌帕替尼校正比值比6.38(95%CI 2.11-19.23,P=0.001),英夫利西单抗校正比值比4.49(95%CI 2.05-9.85,P<0.001)。
  • 诱导后,英夫利西单抗(72.2%)和乌帕替尼(59.5%)的PRO-2应答率仍最优。
  • 与MES 2患者相比,MES 3患者对乌司奴单抗、托法替布、维得利珠单抗和米吉珠单抗的早期及诱导后应答几率降低。

临床怎么用

  • 对于生物制剂初治的重度内镜下UC患者,可优先考虑英夫利西单抗或乌帕替尼以快速控制症状。
  • 基线内镜严重程度可能影响治疗选择,MES 3患者对部分药物应答可能较差。

局限性

  • 为事后分析,可能存在混杂因素。
  • 仅纳入生物制剂初治患者,结论不适用于经治患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Rapid symptom control is critical in managing ulcerative colitis (UC), especially in patients with severe disease. Although multiple advanced therapies are approved for moderate to severe UC, data comparing their speed of onset are limited. We compared the onset and induction efficacy of advanced therapies for UC among biologic-naïve patients with severe endoscopic disease (Mayo endoscopic score [MES] of 3) and explored differential responses in patients with moderate (MES 2) vs severe endoscopic disease. METHODS: This was a post hoc analysis using individual participant-level data from 11 randomized controlled trials. Biologic-naïve patients with MES 3 disease receiving standard induction regimens of infliximab, adalimumab, golimumab, vedolizumab, ustekinumab, mirikizumab, tofacitinib, or upadacitinib were included. The primary outcome was early PRO-2 response, defined as ≥50% reduction in stool frequency and rectal bleeding scores at 2 weeks postbaseline. Secondary outcomes included postinduction clinical remission and PRO-2 remission. Logistic regression models adjusted for baseline covariates were used. RESULTS: A total of 1,781 biologic-naïve patients with MES 3 disease were included. Infliximab (35.1%) and upadacitinib (32.4%) demonstrated the highest early PRO-2 response rates. Compared with placebo, the highest odds of response were observed with upadacitinib (adjusted odds ratio: 6.38 [95% CI: 2.11-19.23], P = 0.001) and infliximab (adjusted odds ratio 4.49 [95% CI: 2.05-9.85], P < 0.001). At postinduction, infliximab (72.2%) and upadacitinib (59.5%) again demonstrated superior PRO-2 response rates. In comparison to MES 2 patients, those with MES 3 had reduced odds of early and postinduction response for several therapies, particularly ustekinumab, tofacitinib, vedolizumab, and mirikizumab. DISCUSSION: Among biologic-naïve UC patients with severe endoscopic disease, infliximab and upadacitinib had the highest rates of week 2 and postinduction PRO-2 response. Baseline disease activity may help to better inform treatment choices.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Wong ECL, Jairath V, Dulai PS, et al. Infliximab and Upadacitinib Demonstrate Superior Early Onset of Efficacy in Biologic-Naïve Ulcerative Colitis With Severe Endoscopic Disease. Am J Gastroenterol. 2026. PMID: 41626838. doi:10.14309/ajg.0000000000003940

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。